Endovascular Treatment of Acute Ischemic Stroke With Underlying Intracranial Artery Stenosis (NCT06260969) | Clinical Trial Compass
UnknownNot Applicable
Endovascular Treatment of Acute Ischemic Stroke With Underlying Intracranial Artery Stenosis
China470 participantsStarted 2022-09-01
Plain-language summary
The study is a prospective multicentre registry study. Patients admitted to 10 stroke centres nationwide from September 2022 to September 2025 with acute ischaemic stroke due to large vessel occlusion considering underlying ICAS and treated with emergency endovascular thrombolysis were included for analysis. Patients who met the general inclusion criteria underwent thrombectomy and the necessary remedial treatment.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* CT scan to exclude intracranial haemorrhage;CT angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction angiography showing occlusion of the distal intracranial carotid artery or the first segment of the middle cerebral artery;ELVO with a base ICAS of \> 70%;Mechanical thrombectomy within 6h after symptom onset in ischemic stroke;NIHSS≥6;receiving endovascular treatments;informed consent form signed by the patient or their legal representatives.
Exclusion Criteria:
* Hemorrhagic body, coagulation factor deficiency or oral anticoagulant therapy(INR \> 3.0);Baseline platelet count \<50,000/µL;Baseline blood glucose \<50mg/dL or \>400mg/dL;Intractable hypertension(systolic blood pressure \>220 mmHg or diastolic blood pressure \>110 mmHg) that cannot be controlled by medication;Patients intubated without a NIHSS score assessed by a neurologist or emergency physician prior to intubation;Stroke attack with epilepsy affecting baseline NIHSS score;End-stage diseases leading to less than one year of expected survival for patients;Severe allergy to contrast media;Patients with renal insufficiency (blood creatinine ≥ 3 mg/dL);Female patients who are pregnant or breastfeeding;The patient is participating in other drugs or device studies that may affect this study;Patient with cerebral vasculitis
What they're measuring
1
Proportion of patients achieving a clinical prognosis of mRS 0-2 at 90 days
Timeframe: patients achieve a clinical prognosis of mRS 0-2 at 90 days